Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 2Sarcoma 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 9Nivolumab 4budigalimab 2belinostat 2Pemetrexed 2Ipilimumab 2Cyclophosphamide 2Cisplatin 2Carboplatin 2venetoclax 1tocilizumab 1tislelizumab 1talazoparib 1spartalizumab 1rovalpituzumab tesirine 1ribociclib 1rebastinib 1obinutuzumab 1naptumomab estafenatox 1fludarabine 1epacadostat 1enzalutamide 1durvalumab 1cabozantinib 1abemaciclib 1Valacyclovir 1Sorafenib 1Sirolimus 1Quality of Life 1Plicamycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × LY3023414 × Breast × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡